Court Says OxyContin Patent Is Invalid

The financial consequence of the decision could be significant for Purdue. Currently, 65 lawsuits have been filed by insurers and others seeking to force the drug maker to disgorge "monopoly," or excessive, profits as a result of the improper patent and the higher prices OxyContin commanded as a result of it. Any damages awarded against Purdue in those cases could be substantial because OxyContin is an expensive drug and because the law allows for a potential tripling of any awards in such cases as a way of penalizing a manufacturer. (That's gotta hurt)


Court Says OxyContin Patent Is Invalid - New York Times

No comments:

Blog Archive